Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.
Publication/Presentation Date
5-1-2019
Abstract
Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous stem cell transplantation has resulted in improved clinical outcomes and better quality of life for MM patients. Elderly patients, comprising the majority of MM population, have a higher incidence of age-related comorbidities, frailty and organ dysfunction which complicates the coordination of treatment and limits the selection of therapies. Even in the era of multiple chemotherapeutic options, the clinical heterogeneity of the myeloma patients' demands personalized treatments which often require dose-adjustments or dose delays. The use of reduced-dose regimens and various comorbidity indices has improved clinical outcome and regimen tolerability in MM patients with renal, neurological and bone abnormalities. We focus on advancements in the treatment of multiple myeloma with the goal to guide clinicians towards patient-specific management.
Volume
137
First Page
18
Last Page
26
ISSN
1879-0461
Published In/Presented At
Fraz, M. A., Warraich, F. H., Warraich, S. U., Tariq, M. J., Warraich, Z., Khan, A. Y., Usman, M., Ijaz, A., Tenneti, P., Mushtaq, A., Akbar, F., Shahid, Z., Ali, Z., Fazeel, H. M., Rodriguez, C., Nasar, A., McBride, A., & Anwer, F. (2019). Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Critical reviews in oncology/hematology, 137, 18–26. https://doi.org/10.1016/j.critrevonc.2019.02.011
Disciplines
Medicine and Health Sciences
PubMedID
31014512
Department(s)
Department of Medicine, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article